Ronja Christensen

Ronja Christensen

Auto-generated profile, based on publicly available information

Ronja Christensen

Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, United Kingdom

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2025 in Landscape and Urban Planning
Verified
Journal Article
Open access
RCRonja Christensen
Ronja Christensen
CFCharlotte Constable Fernandez
Charlotte Constable Fernandez
NTNoémie Topalian
Noémie Topalian
LVLaura Vaughan
Laura Vaughan
KKKimon Krenz
Kimon Krenz
AFAnne-Kathrin Fett
Anne-Kathrin Fett

20 December 2024 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
RCRonja Christensen
Ronja Christensen
AJAmy Jolly
Amy Jolly
CYCharmaine Yam
Charmaine Yam
MYMarios C Yiannakas
Marios C Yiannakas
ATAhmed Toosy
Ahmed Toosy
OCOlga Ciccarelli
Olga Ciccarelli
Background: Cognitive decline in multiple sclerosis (MS) is associated with neuro-axonal loss, quantifiable by optical coherence tomography (OCT). Associations between OCT measures and cognition in relapsing-remitting MS (RRMS) remain incompletely investigated, particularly the added value of OCT when combined with magnetic resonance imaging (MRI). We investigated the contributions of OCT and MRI while applying stringent criteria to control for subclinical optic neuropathy. Methods: In this cross-sectional study, 137 RRMS patients underwent OCT, Brief International Cognitive Assessment for MS (BICAMS), Expanded Disability Status Scale (EDSS) and brain MRI (lesion load, grey and white matter volume); associations were explored using linear regression models. Results: RRMS patients (aged 40.88 ± 10.6 years; disease duration 7.95 ± 7.39 years; EDSS 2; 0–6.5) were studied. Of BICAMS, 50.36% showed impaired Symbol Digit Modalities Test (SDMT), 37.23% impaired Brief Visuospatial Memory Test and 5.11% impaired California Verbal Learning and Memory Test; better SDMT performance was associated with thicker ganglion cell-inner plexiform (GCIPL) layers for eyes unaffected by optic neuritis ( B = 0.23, 95% CI = (0.01–0.44), p = 0.03), but not when MRI measures were included ( B = 0.18, CI = (−0.03 to 0.38), p = 0.09). Conclusion: GCIPL thinning correlates with SDMT, supporting OCT as a biomarker of cognitive dysfunction. However, GCIPL did not uniquely predict SDMT performance when including MRI measures, suggesting limited utility of OCT in predicting cognitive performance over MRI in RRMS.

25 September 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
RCRonja Christensen
Ronja Christensen
ACAlessandro Cruciani
Alessandro Cruciani
SASarmad Al-Araji
Sarmad Al-Araji
ABAlessia Bianchi
Alessia Bianchi
DCDeclan Chard
Declan Chard
OCOlga Ciccarelli
Olga Ciccarelli
Purpose: Multiple sclerosis (MS) is a chronic neurological condition that affects approximately 150 000 people in the UK and presents a significant healthcare burden, including the high costs of disease-modifying treatments (DMTs). DMTs have substantially reduced the risk of relapse and moderately reduced disability progression. Patients exhibit a wide range of responses to available DMTs. The Predicting Optimal INdividualised Treatment response in MS (POINT-MS) cohort was established to predict the individual treatment response by integrating comprehensive clinical phenotyping with imaging, serum and genetic biomarkers of disease activity and progression. Here, we present the baseline characteristics of the cohort and provide an overview of the study design, laying the groundwork for future analyses. Participants: POINT-MS is a prospective, observational research cohort and biobank of 781 adult participants with a diagnosis of MS who consented to study enrolment on initiation of a DMT at the Queen Square MS Centre (National Hospital of Neurology and Neurosurgery, University College London Hospital NHS Trust, London) between 01/07/2019 and 31/07/2024. All patients were invited for clinical assessments, including the expanded disability status scale (EDSS) score, brief international cognitive assessment for MS and various patient-reported outcome measures (PROMs). They additionally underwent MRI at 3T, optical coherence tomography and blood tests (for genotyping and serum biomarkers quantification), at baseline (i.e., within 3 months from commencing a DMT), and between 6–12 (re-baseline), 18–24, 30–36, 42–48 and 54–60 months after DMT initiation. Findings to date: 748 participants provided baseline data. They were mostly female (68%) and White (75%) participants, with relapsing–remitting MS (94.3%), and with an average age of 40.8 (±10.9) years and a mean disease duration of 7.9 (±7.4) years since symptom onset. Despite low disability (median EDSS 2.0), cognitive impairment was observed in 40% of participants. Most patients (98.4%) had at least one comorbidity. At study entry, 59.2% were treatment naïve, and 83.2% initiated a high-efficacy DMT. Most patients (76.4%) were in either full- or part-time employment. PROMs indicated heterogeneous impairments in physical and mental health, with a greater psychological than physical impact and with low levels of fatigue. When baseline MRI scans were compared with previous scans (available in 668 (89%) patients; mean time since last scan 9±8 months), 26% and 8.5% of patients had at least one new brain or spinal cord lesion at study entry, respectively. Patients showed a median volume of brain lesions of 6.14 cm3, with significant variability among patients (CI 1.1 to 34.1). When brain tissue volumes z-scores were obtained using healthy subjects (N=113, (mean age 42.3 (± 11.8) years, 61.9% female)) from a local MRI database, patients showed a slight reduction in the volumes of the whole grey matter (−0.16 (−0.22 to –0.09)), driven by the deep grey matter (−0.47 (−0.55 to –0.40)), and of the whole white matter (−0.18 (−0.28 to –0.09)), but normal cortical grey matter volumes (0.10 (0.05 to 0.15)). The mean upper cervical spinal cord cross-sectional area (CSA), as measured from volumetric brain scans, was 62.3 (SD 7.5) mm2. When CSA z-scores were obtained from the same healthy subjects used for brain measures, patients showed a slight reduction in CSA (−0.15 (−0.24 to –0.10)). Future plans: Modelling with both standard statistics and machine learning approaches is currently planned to predict individualised treatment response by integrating all the demographic, socioeconomic, clinical data with imaging, genetic and serum biomarkers. The long-term output of this research is a stratification tool that will guide the selection of DMTs in clinical practice on the basis of the individual prognostic profile. We will complete long-term follow-up data in 4 years (January 2029). The biobank and MRI repository will be used for collaborative research on the mechanisms of disability in MS.

12 April 2025 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
RCRonja Christensen
Ronja Christensen
AJAmy Jolly
Amy Jolly
CYCharmaine Yam
Charmaine Yam
MYMarios C Yiannakas
Marios C Yiannakas
ATAhmed Toosy
Ahmed Toosy
OCOlga Ciccarelli
Olga Ciccarelli

1 September 2026 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Closed access
ACAlessandro Cruciani
Alessandro Cruciani
EOEmanuele Olivieri
Emanuele Olivieri
RCRonja Christensen
Ronja Christensen
SASarmad Al-Araji
Sarmad Al-Araji
SFSamih Fourali
Samih Fourali
OCOlga Ciccarelli
Olga Ciccarelli